Comparative data for therapies in multiple sclerosis (MS) are scarce. Researchers from the Department of Neuroscience, University of Florence, Italy, have retrospectively compared long-term outcomes between patients treated with beta-interferons (IFNs) or azathioprine (AZA) in relapsing remitting MS and find the treatment options to be equally effective in terms of disability outcomes and annualized relapse rate.